Chief investigator:Ivan Koychev
Co-investigators:Amanda I. Adler
Rury R. Holman
Sponsor:University of Oxford
Funder:Novo Nordisk A/S
Reference number:EudraCT 2021-003328-34
ISAP examines the effects of oral semaglutide, a glucagon-like protein-1 receptor agonist used for diabetes, on the build-up of proteins in the brain characterising Alzheimer’s Disease (amyloid and tau), brain inflammation, and people’s memory and thinking abilities. People included in ISAP are at higher risk of developing Alzheimer’s Disease because of having the protein amyloid in their brains.
One-year randomised, double-blind, placebo-controlled, parallel-group, superiority trial led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk. ISAP will recruit 88 volunteers with high brain amyloid (so-called ‘amyloid-positive’) currently living without dementia from 5 UK clinical sites in Oxford, London (Imperial College and University College), Exeter and Bristol.
New Clinical Trial to Test Drug for Diabetes in Reducing Risk of Alzheimer's Dementia
- Lack of effective treatments for Alzheimer's dementia is one of key challenges to modern medicine and society
A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer's dementia.
The Impact of Semaglutide in Amyloid Positivity (ISAP) trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in: Oxford, Imperial College London, University College London, Exeter, and Bristol....